Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2021-04-30 Annual Report
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
10-K/A
Annual Report FY 2020
2021-04-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 28, 2021. It announces an event regarding the receipt of a Complete Response Letter (CRL) from the FDA related to a Biologics License Application (BLA). The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3474 characters, which is relatively short and primarily serves as an announcement of an event rather than a full financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2021-04-28 English
10-K
Annual Report FY 2020
2021-03-30 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing its financial results for the fiscal year ended December 31, 2020, and a business update. The document itself is short (3740 characters) and primarily serves to furnish the press release as an exhibit. It explicitly states that the information is not "filed" for certain regulatory purposes and is a press release announcement rather than the full financial report. This fits the pattern of an Earnings Release (ER) announcement, as it is the initial announcement of quarterly/periodical financial results with key highlights only, not the full Annual Report (10-K). Therefore, the correct classification is Earnings Release (ER).
2021-03-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text includes a press release about positive topline results from a Phase III clinical trial, attached as an exhibit. There are no detailed financial statements or comprehensive financial analysis present. The document is short (3502 characters) and primarily announces an event rather than providing a full report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-02-23 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-02-16 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.